An expanded access record providing Acellular Tissue Engineered Vessel (ATEV) in Vascular Diseases and End Stage Renal Disease on Dialysis, sponsored by Humacyte, Inc.. Temporarily not available. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by Humacyte, Inc. · Expanded access
Individual patient expanded access requests may be considered for patients who have no other treatment options and are not eligible for an ATEV clinical study.
Procedure for Requesting Expanded Access:
The treating physician requesting expanded access must contact Humacyte directly with the basis for the request. Please include the Investigator's contact information so that Humacyte may follow up with the Investigator directly.
General Criteria:
The Humacyte Expanded Access Committee will evaluate and respond to each expanded-access request received on a case-by-case basis. Humacyte will consider the nature of the request, the patient's health, the available medical and scientific information about the investigational product, the balance of risk and potential benefit to the patient, the availability of investigational product, and the potential regulatory impact.
Anticipated Timing:
Humacyte will acknowledgement receipt of each Investigator request within ten (10) business days or less.
-
Exclusion Criteria:
-
No study locations are listed for this record.
Expanded access is arranged between your doctor and the company. Ask your care team to contact the provider listed on this record.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Humacyte, Inc.